Drug side-effects are crucial issues in both the premarket drug developing process and post-market drug clinical applications. They contribute to one-third of drug failures and cause significant fatality and severe morbidity. Thus the early identification of potential drug sideeffects is of great interests. Most existing methods essentially rely on leveraging few drug similarities directly for side-effect predictions, ignoring the performance improvement by drug similarity integration and optimization. In this study, we proposed an optimized drug similarity framework (ODSF) to improve the performance of sideeffect predictions. First, this framework integrates four different drug similarities into a comprehensive similarity. Next, the comprehensive similarity is optimized via clustering and then enhanced by indirect drug similarity. Finally, the optimized drug similarity is employed for sideeffect predictions. The performance of ODSF was evaluated on simulative side-effect predictions of 917 drugs from the DrugBank. Extensive comparison experiments demonstrate that ODSF is competent to capture drug features from diverse perspectives and the prediction performance is significantly improved owing to the optimized drug similarity.
Introduction
Drug side-effects are effects which are secondary to the intended effects [1] . They have drawn attention of the society because they cause a large number of morbidity and fatality every year. Therefore, the early identification of potential side-effects to avoid serious harms and financial loss is of great importance. For this purpose, experimental approaches which test compounds with in vitro biochemical and cellular assays were proposed. However, drug side-effect prediction remains challenging because of the expensive and long-term process of experimental approaches. In recent years, several computational methods have been proposed for side-effect predictions. Most of these methods are based on the hypothesis that similar drugs are more likely to share the same side-effects. According to the similarity types they adopt, these methods can be classified as follows:
(1) Target-protein similarity based methods, which utilize target-protein similarity directly or pathway similarity which involves target-proteins indirectly to measure the similarity between drugs. Two previous studies demonstrated that side-effects and target proteins have strong relations [2] [3] . Huang et al. developed a novel computational framework by combining clinical observation data with drug target data to predict side-effects of trial drugs [4] . Their results showed that the prediction performance improved significantly owing to incorporating prior knowledge including the drug target data. Pathways are series of actions among molecules in a cell. They can trigger the assembly of new molecules, including proteins. Previous enrichment analyses using KEGG and Gene Ontology reveal that the correlated sets were significantly enriched with proteins involved in the same biological pathways [5] . Side-effects can be seen as phenotypic outcomes by drugs targeting proteins in the same correlated set. Thus there is some-how relationship between side-effects and pathways. Fukuzaki et al. developed an efficient algorithm method named "CoopeRative Pathway Enumerator" to identify cooperative pathways which share common active conditions [6] . Finally, these identified cooperative pathways were leveraged to predict drug side-effects and achieved satisfactory results.
(2) Chemical structure similarity based methods, which measure the drug similarity by their chemical structures. Atias et al. conducted the canonical correlation analysis (CCA) between drug chemical structures and side-effects to predict new side-effects [7] . It is one of the pioneering work on predicting multiple side-effects at a time. Yoshihiro et al. tried to improve side-effect prediction by integrating drug chemical structures and target proteins [8] . Simulative prediction of side-effects from the Drug-Bank demonstrated that the prediction performance was improved significantly by integration of the two information sources.
Most existing computational prediction methods focus on prediction from one or few drug similarity sources. Too few similarity sources may not capture enough drug features. Moreover, these methods utilize drug similarities directly for predictions, ignoring the value of optimization from such similarities and indirect similarities that could improve the prediction performance. In this study, we proposed an optimized drug similarity framework (ODSF) to improve the side-effect prediction performance. This framework integrates four different drug similarities into a comprehensive similarity first. Next the comprehensive similarity is further optimized via clustering and then enhanced by indirect similarity. Finally, the optimized drug similarity is used for side-effect predictions.
Materials

Drug Side-effect Profiles
The side-effect data set was downloaded from SIDER [9] . We focus on side-effects of drugs which are grouped as "Small Molecules" in DrugBank. Our basic idea lies in predicting side-effects by drug similarities. Therefore, those drugs whose similarity information are not available were removed. Finally, we obtained a dataset constituted by 917 drugs, 500 side-effects and 78,855 drug side-effect associations.
Drug Similarity Data
Four types of drug similarity will be integrated as the original comprehensive drug similarity (OCDS) using the following formula.
A. Chemical Structure Similarity The chemicalstructure fingerprints of drugs were retrieved using CDK from their SMILES files downloaded from the DrugBank. For a drug d, it can be represented by its fingerprint
Then the chemical similarity score between drug d j and drug d k is given by:
where ∧ and ∨ are bitwise "and" and "or" operators respectively; f j l and f k l are the l th bit of fingerprints of drug d j and drug d k respectively.
B. Drug Target Protein Similarity The similarity between two proteins is calculated based on the overlapping rate of their associated Gene Ontology (GO) terms. Suppose GO m and GO n are the GO term sets for protein p m and protein p n respectively, the similarity score between p m and p n would be
where ∩ and ∪ are intersection and union operators respectively. The GO terms of target proteins were downloaded from the EMBL-EBI website. Then the drug target protein similarity between each pair of drugs was calculated by integrating protein similarities of their target proteins.
where N j and N k are the total number of proteins in the interacted protein sets of drug d j and drug d k respectively. C. Drug Substituent Similarity The drug substituent similarity between drug d j and drug d k is calculated via Jaccard score which is defined as follows:
where SU B j and SU B k are the substituent sets of drug d j and d k respectively.
D. Drug Therapeutic Similarity
The Anatomical Therapeutic Chemical (ATC) codes used in this study were extracted from the DrugBank. There are 5 levels in the ATC code. Consequently, we calculated the drug therapeutic similarity at each level separately first. The l th level drug therapeutic similarity (S l ) between the drug d j and d k is defined as follows:
where AT C l (d j ) denotes the l th level ATC code for drug d j . The average value of the five-level similarity scores is used as the therapeutic similarity of a drug pair:
where n = 5, is the total number of ATC code levels.
Methods
The overall framework of ODSF is illustrated in Figure  1 . At the beginning, drugs and side-effects which don't satisfy the requirements are removed. Then four different drug similarities are integrated as the original comprehensive drug similarity. Next the original comprehensive similarity is further optimized via ClusterONE clustering and indirect similarity optimization. After that, the two types of drug similarities are integrated as the optimized similarity. Later, a balanced drug training set is built for each side-effect using the proposed strategy. Afterwards, drugs are vectorized according to their optimized similarities with each drug in the training set. Finally, a classifier is built and trained for each side-effect. Corresponding classifier is employed to predict potential drugs which could cause the side-effect. 
Drug Similarity Optimization
A. Optimization based on Clustering
Based on the hypothesis that similar drugs are more likely to share the same side-effects, we proposed to optimize drug similarity via clustering. We first built a weighted drug sharing network based on the known drugside-effect associations, called DrugNetwork. In DrugNetwork, the vertexes V = {d 1 , d 2 , . . . , d n } denote the set of n drugs, the edges represent the drug-drug associations, and the edge weights denote the number of common sideeffects shared by corresponding drug pairs. Then we leveraged a graph clustering method "ClusterONE" to identify potential drug clusters in DrugNetwork. According to ClusterONE, the cohesiveness of a cluster C i is defined as follows:
where W in (C i ) is the sum of the edge weights within the cluster C i , W bound (C i ) denotes total weights of edges which connect vertexes from cluster C i to the rest of the DrugNetwork. For drug d j and d k belong to the same cluster C i , their similarity value will be optimized as
where Coh(C i ) is the cohesiveness of cluster C i and Simcom(d j , d k ) is the OCDS between drug d j and drug d k . Note for the cluster-based optimized similarity between two different drugs which is equal or great than 1, we normalized it as 0.9999. B. Optimization by Indirect Drug Similarity Indirect drug similarity refers to similarity values which are not measured by drug properties directly but by existing similarity. In this study, we developed a propagation framework to compute the indirect similarity between each drug pair. Here we leverage a drug pair, i.e., d j and d k , to illustrate the process of computing indirect drug similarity. Suppose d j and d k both belong to the drug set D = {d 1 , d 2 , . . . , d n }. Then their indirect drug similarity will be as follows: Simcom(d j , d i ) and Simcom(d i , d k ) are the OCDS between drug d j and d i , and d i and d k respectively (1 ≤ i ≤ n, i = j and i = k).
C. Integration of Optimized Drug Similarity We adopted the following formula to integrate the two different types of drug similarity.
and Simids(d j , d k ) are the cluster-based optimized similarity and indirect similarity.
Optimization via Building Balanced Drug Training Sets
After careful analysing, we found that the number of labeled drugs for different side-effects is different. Therefore, the training set will be unbalanced if we directly take the labeled and unlabeled drugs as positive and negative samples respectively. However, unbalanced training sets would largely degrade the prediction performance. Thus, to improve the prediction performance, we proposed the following steps to build a balanced drug training set for each side-effect. (a) Obtain the smaller number n s from the labeled drug number and the unlabeled drug number; (b) Select n s labeled drugs and n s unlabeled drugs to form the positive and negative sample set respectively.
Results
F1-Score and macro-averaging F1-Score are leveraged to evaluate the prediction performance in this study. To demonstrate the improvement of our method, we evaluated the performance of side-effect prediction based on OCDS and our optimization framework over the 5-folds experiment. Four different classifiers namely KNN (K-Nearest Neighbors), SVM (Support Vector Machine), ELM (Extreme Learning Machine) and RBF (Radial Basis Function) network were employed in the experiment. Related results are illustrated in Figure 2 and Table 1 . Figure 2 shows the scatter plots of F1-Scores using the two methods, where x-axis denotes F1-Scores based on OCDS and y-axis denotes F1-Scores based on ODSF. To better visualize the comparison results, we added a reference line "y = x" on which F1-Scores are equal to each sub-figure.
It can be seen clear from Figure2 that most dots distribute on the top-left area. It means the prediction performance based on our ODSF outperformed that based on OCDS for most side-effects. To investigate how much improvement is made by our method, we further calculated the macroaveraging F1-Scores of the top 50, top 100, top 200 and all side-effects as listed in Table 1 . Clearly, the predictions based on our optimization framework achieved signicantly higher performance than that base on OCDS. For example, for the four classifiers from KNN to ELM, the macroaveraging F1-Score improvement of top-100 side-effects is 6.9%, 18.4%, 19.1% and 9.3%. 
Conclusion
In this study, we proposed a method to optimize drug similarity for side-effect prediction. First, four different types of similarities which could measure the similarity between drugs from different perspectives were fused together as OCDS. Then a clustering-based method was adopted to optimize OCDS. Next, indirect drug similarity which could reinforce the direct drug similarity was computed. Finally, the clustering-optimized similarity and indirect similarity were integrated into a unified framework for drug side-effect prediction. Extensive comparison experiments on drugs from DrugBank demonstrate that our optimized similarity based prediction method achieved much better performance than that based on OCDS.
